A Study About Modified RNA Vaccines Against Influenza in Healthy Adults
NCT ID: NCT06436703
Last Updated: 2026-01-09
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
PHASE2
1202 participants
INTERVENTIONAL
2024-05-23
2025-02-05
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
* safe; and
* how these vaccines produce an immune response in generally healthy adults. Immune response is the way the body protects itself against things it sees as harmful or foreign.
RNA (also called ribonucleic acid) is one of two types of nucleic acid made by cells. RNA contains information that has been copied from DNA (the other type of nucleic acid). Cells make several different forms of RNA, and each form has a specific job in the cell. Many forms of RNA have functions related to making proteins. RNA is also the genetic material of some viruses instead of DNA. RNA can be made in the laboratory and used in research studies. Also called ribonucleic acid.
Influenza is term used for flu illness. It is an infection caused by a virus that affects your mouth, nose, and throat.
The study is seeking for participants who:
* are at least 18 years of age
* have not received an influenza vaccine within the last 6 months
* are generally healthy
This study will be divided into three sub-studies: Substudy A (SSA), Substudy B (SSB), and Substudy C (SSC).
All participants, regardless of sub-study, will receive 1 dose of either of the following vaccines as an injection into their arm:
* 1 of the modRNA influenza vaccines that is being studied; or
* an approved influenza vaccine approved for use in their respective age group.
Participants will be involved in this study for about 6 months. During this time, participants will have at least 3 clinic visits.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
A Study to Evaluate the Safety, Tolerability, and Immunogenicity of a Modified RNA Vaccine Against Influenza
NCT05052697
A Study to Investigate the Immunogenicity, Reactogenicity, and Safety of mRNA-1083 (Influenza and COVID-19) Vaccine in Adults ≥18 to <65 Years of Age
NCT06864143
A Study of mRNA-1011.1, mRNA-1011.2, and mRNA-1012.1 Candidate Seasonal Influenza Vaccines in Healthy Adults
NCT05827068
A Study To Learn About The Study Vaccine (Called Self-Amplifying Ribonucleic Acid (RNA)) For The Prevention of Influenza
NCT05227001
A Study to Evaluate a Modified RNA Vaccine Against Influenza in Adults 18 Years of Age or Older
NCT05540522
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
PREVENTION
QUADRUPLE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
SSA: Influenza ModRNA Vaccine 2A
\- Single Dose on Day 1
Influenza ModRNA Vaccine
Intramuscular injection
SSA: Influenza ModRNA Vaccine 3A
\- Single Dose on Day 1
Influenza ModRNA Vaccine
Intramuscular injection
SSA: Influenza ModRNA Vaccine 4A
\- Single Dose on Day 1
Influenza ModRNA Vaccine
Intramuscular injection
SSA: Influenza ModRNA Vaccine 5A
\- Single dose on Day 1
Influenza ModRNA Vaccine
Intramuscular injection
SSA: QIV1
\- Single dose on Day 1
Quadrivalent Influenza Vaccine (QIV)
Intramuscular injection
SSB: Influenza ModRNA Vaccine 3B
\- Single Dose on Day 1
Influenza ModRNA Vaccine
Intramuscular injection
SSB: Influenza ModRNA Vaccine 4B
\- Single Dose on Day 1
Influenza ModRNA Vaccine
Intramuscular injection
SSB: Influenza ModRNA Vaccine 5B
\- Single dose on Day 1
Influenza ModRNA Vaccine
Intramuscular injection
SSB: QIV2
\- Single Dose on Day 1
Quadrivalent Influenza Vaccine (QIV)
Intramuscular injection
SSB: QIV3
\- Single Dose on Day 1
Quadrivalent Influenza Vaccine (QIV)
Intramuscular injection
SSC: Influenza ModRNA Vaccine 3C
\- Single Dose on Day 1
Influenza ModRNA Vaccine
Intramuscular injection
SSC: Influenza ModRNA Vaccine 4C
\- Single Dose on Day 1
Influenza ModRNA Vaccine
Intramuscular injection
SSC: Influenza ModRNA Vaccine 5C
\- Single Dose on Day 1
Influenza ModRNA Vaccine
Intramuscular injection
SSC: Influenza ModRNA Vaccine 6C
\- Single Dose on Day 1
Influenza ModRNA Vaccine
Intramuscular injection
SSC: Influenza ModRNA Vaccine 7C
\- Single Dose on Day 1
Influenza ModRNA Vaccine
Intramuscular injection
SSC: Influenza ModRNA Vaccine 8C
\- Single Dose on Day 1
Influenza ModRNA Vaccine
Intramuscular injection
SSC: Influenza ModRNA Vaccine 9C
\- Single dose on Day 1
Influenza ModRNA Vaccine
Intramuscular injection
SSC: QIV2
\- Single Dose on Day 1
Quadrivalent Influenza Vaccine (QIV)
Intramuscular injection
SSC: QIV3
\- Single Dose on Day 1
Quadrivalent Influenza Vaccine (QIV)
Intramuscular injection
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Influenza ModRNA Vaccine
Intramuscular injection
Quadrivalent Influenza Vaccine (QIV)
Intramuscular injection
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* participants ≥18 years of age.
* generally healthy participants.
Substudy C ONLY:
\- receipt of licensed influenza vaccination for the 2023-2024 flu season at least 6 months ago.
Exclusion Criteria
* diagnosis of influenza (by clinical testing) in the last 6 months.
* immunocompromised individuals with known or suspected immunodeficiency
* receipt of any investigational or licensed influenza vaccines within 6 months.
18 Years
ALL
Yes
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Pfizer
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Pfizer CT.gov Call Center
Role: STUDY_DIRECTOR
Pfizer
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Alliance for Multispecialty Research, LLC
Mobile, Alabama, United States
Headlands Research - Scottsdale
Scottsdale, Arizona, United States
Anaheim Clinical Trials, LLC
Anaheim, California, United States
Orange County Research Center
Lake Forest, California, United States
Artemis Institute for Clinical Research
San Diego, California, United States
Diablo Clinical Research, Inc.
Walnut Creek, California, United States
Clinical Research Consulting
Milford, Connecticut, United States
Indago Research & Health Center, Inc
Hialeah, Florida, United States
Research Centers of America ( Hollywood )
Hollywood, Florida, United States
Research Centers of America
Hollywood, Florida, United States
Palm Springs Community Health Center
Miami Lakes, Florida, United States
Clinical Neuroscience Solutions, Inc.
Orlando, Florida, United States
Headlands Research Orlando
Orlando, Florida, United States
Qps-Mra, Llc
South Miami, Florida, United States
East-West Medical Research Institute
Honolulu, Hawaii, United States
Alliance for Multispecialty Research, LLC
New Orleans, Louisiana, United States
Prism Research LLC dba Nucleus Network
Saint Paul, Minnesota, United States
Clinical Research Professionals
Chesterfield, Missouri, United States
Alliance for Multispecialty Research, LLC
Kansas City, Missouri, United States
Rochester Clinical Research, LLC
Rochester, New York, United States
Duke Vaccine and Trials Unit
Durham, North Carolina, United States
M3 Wake Research, Inc.
Raleigh, North Carolina, United States
DM Clinical Research - Philadelphia
Philadelphia, Pennsylvania, United States
Headlands Horizons LLC
Brownsville, Texas, United States
SMS Clinical Research
Mesquite, Texas, United States
Clinical Trials of Texas, LLC dba Flourish Research
San Antonio, Texas, United States
Clinical Trials of Texas, LLC
San Antonio, Texas, United States
Dynamed Clinical Research, LP d/b/a DM Clinical Research
Tomball, Texas, United States
J. Lewis Research, Inc. / Foothill Family Clinic
Salt Lake City, Utah, United States
J. Lewis Research, Inc. / Foothill Family Clinic South
Salt Lake City, Utah, United States
Charlottesville Medical Research
Charlottesville, Virginia, United States
Alliance for Multispecialty Research, LLC
Norfolk, Virginia, United States
Countries
Review the countries where the study has at least one active or historical site.
Related Links
Access external resources that provide additional context or updates about the study.
To obtain contact information for a study center near you, click here.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
NCT06436703
Identifier Type: REGISTRY
Identifier Source: secondary_id
C4781013
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.